Long-term Follow-Up for RGX-121
← catalyst calendarNCT04597385 · readout ≤ 804 d
Sponsored by REGENXBIO Inc. (industry) · RGNX — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
27actual
Sites
4
Countries
Brazil, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-03-14 | actual | When the study began enrolling |
| Primary completion | Oct 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2020-10-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Mucopolysaccharidosis II
Intervention
- Other: Long-term Follow-Up
Primary outcome
what the primary-completion date above is the date OFLong-term Safety of RGX-121
measured 5 years inclusive of parent study
Permalink · RGNX's whole pipeline · Catalyst calendar · Every registered study · What changed